An iron-acquisition-deficient mutant of Corynebacterium pseudotuberculosis efficiently protects mice against challenge
© Ribeiro et al.; licensee BioMed Central Ltd. 2014
Received: 2 November 2013
Accepted: 25 February 2014
Published: 6 March 2014
Caseous lymphadenitis (CLA) is a chronic disease that affects sheep and goats worldwide, and its etiological agent is Corynebacterium pseudotuberculosis. Despite the economic losses caused by CLA, there is little information about the molecular mechanisms of bacterial pathogenesis, and current immune prophylaxis against infection has been unable to reduce the incidence of CLA in goats. Recently, 21 different mutant strains of C. pseudotuberculosis were identified by random mutagenesis. In this study, these previously generated mutants were used in mice vaccination trials to develop new immunogens against CLA. Based on this analysis, CZ171053, an iron-acquisition-deficient mutant strain, was selected. After challenge with a virulent strain, 80% of the animals that were immunized with the CZ171053 strain survived. Furthermore, this vaccination elicited both humoral and cellular responses. Intracellular survival of the bacterium was determined using murine J774 cells; in this assay, the CZ171053 had reduced intracellular viability. Because iron acquisition in intracellular bacteria is considered one of their most important virulence factors during infection, these results demonstrate the immunogenic potential of this mutant against CLA.
Corynebacterium pseudotuberculosis is a facultative gram-positive intracellular pathogen that is the etiological agent of caseous lymphadenitis (CLA) in sheep and goats. CLA is a chronic debilitating infection, and its main symptoms can be divided into external CLA, which affects superficial lymph nodes, and internal CLA, which leads to the development of abscesses in internal lymph nodes and organs, including the liver, lungs and kidneys [1–3]. This disease has a worldwide distribution and causes economic losses in several countries, principally to producers in developing countries such as Brazil, where sheep and goat breeding are of increasing economic importance [4–10].
Once established in a herd, CLA is difficult to treat because it is generally refractory to antibiotic therapy, which is also very expensive . Therefore, several studies have been conducted to develop vaccines that can effectively control CLA. Although these vaccines are useful and offer reasonable protection, there are several problems associated with their use. All of these vaccines need to be administered at least twice, which contributes to the misuse of the vaccines by farmers and increases the cost. Furthermore, not all vaccines available for use in goats have the same efficacy in sheep, and they are not licensed in all countries [2, 12]. Some experimental vaccines have been tested using different strategies such as vaccines using attenuated or inactivated bacteria, cell wall fractions and DNA [13–25]. These vaccines confer variable levels of protection, but their safety profiles remain questionable mainly because their side effects, which are more intense in goats. These side effects include the formation of lesions or abscesses at the injection site, fever, malaise and reduced milk production [26, 27].
Driven by the paucity of information on the molecular basis of C. pseudotuberculosis virulence, we identified and characterized bacterial genes based on the cellular localization of their products, focusing mainly on those proteins that are anchored and secreted. To identify such genes, we used, for the first time in this species, a reporter transposon-based system named TnFuZ . Using this tool, we identified 34 mutants exhibiting a blue phenotype from a repertoire of 1500 kanamycin-resistant mutants . By sequencing the transposon insertion site in these mutants, we identified 21 different loci encoding fimbrial and transport subunits, hypothetical proteins and proteins with unknown-function in C. pseudotuberculosis. In this present study, we tested these mutants in immunization assays to assess their virulence potential and their capacity to protect mice against challenge. Furthermore, we studied the cytokine and immunoglobulin production induced by the best vaccine candidates.
Materials and methods
Bacterial strains and growth conditions
The following strains were used: the previously generated C. pseudotuberculosis TnFuZ recombinant strains , the T1 pathogenic wild-type parental strain and the caprine-pathogenic MIC-6 strain. The strains were grown aerobically in Brain Heart Infusion broth (BHI, Oxoid Ltd., Hampshire, England) at 37 °C. The mutant strains were grown in the presence of kanamycin (kanamycin sulphate, 25 μg/mL; solid and liquid media) and 5-bromo-4-chloro-3-indolylphosphate (BCIP, 40 μg/mL; Sigma-Aldrich Co., St. Louis, MO, USA; solid medium), a substrate that allows the recovery of C. pseudotuberculosis insertional mutant colonies with positive alkaline phosphatase activity.
One hundred fifty BALB/c mice between six and eight weeks of age, that were susceptible to C. pseudotuberculosis infection, were used in this assay. They were provided by the Animal Care Facility of the Biological Sciences Institute from the Federal University of Minas Gerais and were handled according to the guidelines of the UFMG Ethics Committee on Animal Testing.
Immunization assay, challenge and assessment of protection level
The immunization schedule was as follows: twenty-two groups of five mice each were intraperitoneally inoculated with 2 × 106 Colony forming unit (CFU) of each mutant strain (CZ171049 and CZ171061 with different transposon insertions), with was, the same dose used by Simmons et al. . Another group of five animals received the T1 wild-type strain under the same conditions, and a 24th group of five mice was inoculated with 100 μL of saline solution (0.9% NaCl). The mice were intraperitoneally challenged 21 days after immunization with 2 × 106 C.F.U of the C. pseudotuberculosis MIC-6 virulent strain. The protection conferred by the immunization process was evaluated by comparing the survival of the immunized animals to those inoculated with the T1 wild-type strain and saline solution. The mice were evaluated for four weeks after challenge.
For the second immunization assay, three groups of ten mice each were inoculated with 2 × 106 CFU of the CZ171053 strain, 2 × 106 CFU of the T1 strain or 100 μL of saline solution. The immune protection was evaluated using the procedure described above.
Detection of specific IgG, IgG1 and IgG2a antibodies
Serum samples were taken 21 days after immunization. Blood samples were collected through retro-orbital bleeding. After coagulation, the blood was centrifuged at 3000 rpm for ten minutes. The serum samples were collected and stored at −20 °C. These samples were analysed using an enzyme-linked immunosorbent assay (ELISA) to measure the total levels of specific IgG, IgG1 and IgG2a antibodies. The plates were incubated with 200 μL of the supernatant of a MIC-6C. pseudotuberculosis culture grown for 72 h (total protein concentration of 4 μg/mL); the plates were then incubated for 18 h at 4 °C. The wells were blocked with 0.1% Tween 20 and 10% fat-free milk powder in PBS (pH 7.4) for two hours at room temperature. The plates were then incubated with 100 μL of the serum samples, diluted 1:50 in PBS-Tween, for one hour at 37 °C. The wells were washed three times with PBS-Tween between incubations. Anti-mouse IgG conjugated to horseradish peroxidase (Promega, Madison, WI, USA) was diluted 1:10 000 in PBS-Tween and added to the wells, and the plates were incubated for one hour at 37 °C. The same procedure was performed with horseradish peroxidase-conjugated anti-mouse IgG1 (Promega) diluted 1:5000 and anti-mouse IgG2a (Promega) (diluted 1: 2000). The plates were developed with 200 pmol of o-phenylenediamine (Sigma) and 0.05% H2O2, for ten minutes, and the reaction was stopped with 50 μL of 2 N H2SO4. After incubation for ten minutes at room temperature, the optical density at 492 nm (OD492) was measured.
For the cytokine analysis, five immunized mice from the CZ171053-, T1- and saline-infected groups were sacrificed before challenge, and their spleens were collected aseptically. Erythrocytes were removed by treatment with 0.017 M Tris-ammonium chloride, and the remaining leukocytes were washed twice with PBS (pH 7.4) and suspended in RPMI (RPMI-1640; Gibco BRL, Life technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin. After adjusting the cellular concentrations to 5 × 106 viable cells/mL in 100 μL, the samples were seeded in 96-well tissue culture plates. The cells were stimulated with the supernatant of a 72-h MIC-6C. pseudotuberculosis culture (protein concentration of 4 μg/mL) . The positive control wells were stimulated with concanavalin A (2 μg/mL; Sigma), and culture medium was added to the negative control wells. The supernatants were collected 24 h after stimulation and used for IL-4, IL-10, IFN-γ and TNF-α quantification using commercial sandwich ELISA kits (Duo Set ELISA Development System, R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.
Determination of intracellular survival
J774 macrophage-like cells, derived from murine lymphoma were cultivated in Dulbecco’s modified Eagle essential medium (DMEM, Sigma) supplemented with 5% fetal bovine serum, 50 μg/mL gentamicin and 2.5 μg/mL fungizone at 37 °C in a 5% CO2 atmosphere. The CZ171053 mutant strain and T1 wild-type strain were grown for 48 h at 37 °C, washed three times with PBS, resuspended in DMEM to at a concentration of 106 CFU/mL and used to infect J774 cells (10 bacteria: 1 cell). For the determination of intracellular viability, the infected J774 monolayers were washed six times with PBS and treated with 150 μg/mL gentamicin sulphate (Sigma) then diluted in DMEM for one hour after one, three and six hours of incubation. The cells were washed six times with PBS to eliminate the dead bacteria in the extracellular medium. The monolayers were lysed with 0.5 mL of 0.1% TritonX-100 (Sigma) in PBS, and the supernatant was plated on BHI agar. The number of intracellular bacteria was determined by counting the number of CFU.
The results were expressed as the mean ± standard deviation. The differences among the experimental groups were calculated using one-way ANOVA followed by the Bonferroni (post-test levels of protection and immunoglobulin and cytokine production) or Tukey’s (intracellular viability) tests. The data were considered significantly different when p < 0.05. Both tests were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA) .
Immunization assay, challenge and assessment of protection level
Using a transposon-based random mutagenesis system, 34 alkaline phosphatase-positive recombinant strains of C. pseudotuberculosis were obtained; in these strains transposon insertions were identified at 21 different loci. In this study, 22 of the mutant strains were tested in mice vaccination trials to select potential immunogenic candidates against caseous lymphadenitis.
After selection of the CZ171053 strain as a potential immunogenic candidate, a new immunization assay was performed to evaluate the immunoglobulin- and cytokine-induction profiles after immunization. Three groups of ten mice received the CZ171053 mutant, T1 wild-type strain or 100 μL of saline solution according the immunization schedule described above. Serum samples and splenocytes were collected 21 days after immunization.
Detection of specific IgG, IgG1 and IgG2a antibodies
Intracellular survival determination
The results presented here are surprising because IFN-γ and TNF-α, which are important for the host defence against C. pseudotuberculosis infection [23, 31], were not detected in significant levels in the immunized mice. We cannot exclude the possibility that this unexpected finding is due to the late time-point at which the cytokine levels were analysed. Simmons et al.  evaluated IFN-γ production on the seventh and fourteenth days after the vaccination of mice with live C. pseudotuberculosis and qualitatively detected the production of this cytokine on day 7, but not on day 14, suggesting a self-limiting profile of the immune response. The high production of IL-10 at a late time-point after inoculation was described by Paule et al.  and could be responsible for the low IFN-γ production; this observation suggests that an immune modulatory profile might underlie the inhibition of IFN- γ production observed in our experiments . Additionally, this regulatory profile could be a consequence of an inflammatory reaction that led to the switch from a Th1 to a Th2 profile because cytokines typical of this profile were detected in our ELISA analyses. Furthermore, Paule et al.  observed that after caprine-immunization some animals did not produce IFN-γ but still presented significant protection against the infectious challenge. More accurate analyses should be performed to elucidate the immunological protection mechanisms that are induced by the CZ171053 strain in mice. In our experiments, cytokine production was evaluated 21 days after immunization, and the profile observed might be a modulatory profile after the initial immune response.
Our data on the immune protection, production of immunoglobulins and cytokines and intracellular viability suggest that the CZ171053 mutant has a reduced ability to survive inside the host cells but is still able to induce immunoglobulin and cytokine production. Furthermore, these results are suggestive of attenuation used by an iron-acquisition deficiency. Iron acquisition is essential for bacterial growth in vivo and the protein encoded by the gene that was disrupted in this mutant, ciuA (Gene ID: 9448933), is involved in the transport of iron from ferric citrate. The inability of this mutant to acquire iron might be important for attenuation. The mutant bacteria that invade the host cells are recognized by the immune system and, most importantly, protect the immunized mice upon challenge with a virulent strain. These results, which were obtained using a murine model, suggest that the CZ171053 strain may be used as a potential live vaccine against CLA in other animals such as goats and sheep, which are natural hosts for C. pseudotuberculosis.
The authors are profoundly grateful to Dr Raphael Hirata Jr., from Universidade do Estado do Rio de Janeiro his for technical assistance and to Coordenação de Aperfeiçoamento de Pessoal de Ensino superior (CAPES), Conselho Nacional de Pesquisa (CNPQ) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Fapemig) for funding this project.
- Dorella FA, Pacheco LG, Oliveira SC, Miyoshi A, Azevedo V: Corynebacterium pseudotuberculosis: microbiology, biochemical properties, pathogenesis and molecular studies of virulence. Vet Res. 2006, 37: 201-218. 10.1051/vetres:2005056.View ArticlePubMedGoogle Scholar
- Dorella FA, Pacheco LG, Seyffert N, Portela RW, Meyer R, Miyoshi A, Azevedo V: Antigens of Corynebacterium pseudotuberculosis and prospects for vaccine development. Expert Rev Vaccines. 2009, 8: 205-213. 10.1586/147605126.96.36.199.View ArticlePubMedGoogle Scholar
- Dorella FA, Estevam EM, Pacheco LG, Guimaraes CT, Lana UG, Gomes EA, Barsante MM, Oliveira SC, Meyer R, Miyoshi A, Azevedo V: In vivo insertional mutagenesis in Corynebacterium pseudotuberculosis: an efficient means to identify DNA sequences encoding exported proteins. Appl Environ Microbiol. 2006, 72: 7368-7372. 10.1128/AEM.00294-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Al-Rawashdeh OF, Al-Qudah KM: Effect of shearing on the incidence of caseous lymphadenitis in awassi sheep in Jordan. J Vet Med B Infect Dis Vet Public Health. 2000, 47: 287-293. 10.1046/j.1439-0450.2000.00346.x.View ArticlePubMedGoogle Scholar
- Connor KM, Quirie MM, Baird G, Donachie W: Characterization of United Kingdom isolates of Corynebacterium pseudotuberculosis using pulsed-field gel electrophoresis. J Clin Microbiol. 2000, 38: 2633-2637.PubMed CentralPubMedGoogle Scholar
- Ben Said MS, Ben Maitigue H, Benzarti M, Messadi L, Rejeb A, Amara A: Epidemiological and clinical studies of ovine caseous lymphadenitis. Arch Inst Pasteur Tunis. 2002, 79: 51-57. (in French)PubMedGoogle Scholar
- Binns SH, Bailey M, Green LE: Postal survey of ovine caseous lymphadenitis in the United Kingdom between 1990 and 1999. Vet Rec. 2002, 150: 263-268. 10.1136/vr.150.9.263.View ArticlePubMedGoogle Scholar
- Arsenault J, Dubreuil P, Girard C, Simard C, Bélanger D: Maedi-visna impact on productivity in Quebec sheep focks (Canada). Prev Vet Med. 2003, 59: 125-137. 10.1016/S0167-5877(03)00086-2.View ArticlePubMedGoogle Scholar
- Paton MW, Walker SB, Rose IR, Watt GF: Prevalence of caseous lymphadenitis and usage of caseous lymphadenitis vaccines in sheep flocks. Aust Vet J. 2003, 81: 91-95. 10.1111/j.1751-0813.2003.tb11443.x.View ArticlePubMedGoogle Scholar
- Seyffert N, Guimarães AS, Pacheco LGC, Portela RW, Bastos BL, Dorella FA, Heinemann MB, Lage AP, Gouveia AM, Meyer R, Miyoshi A, Azevedo V: High seroprevalence of caseous lymphadenitis in Brazilian goat herds revealed by Corynebacterium pseudotuberculosis secreted proteins-based ELISA. Res Vet Sci. 2010, 88: 50-55. 10.1016/j.rvsc.2009.07.002.View ArticlePubMedGoogle Scholar
- Williamson LH: Caseous lymphadenitis in small ruminants. Vet Clin North Am Food Anim Pract. 2001, 17: 359-371.PubMedGoogle Scholar
- Windsor PA: Control of caseous lymphadenitis. Vet Clin North Am Food Anim Pract. 2011, 27: 193-202. 10.1016/j.cvfa.2010.10.019.View ArticlePubMedGoogle Scholar
- Billington SJ, Esmay PA, Songer JG, Jost BH: Identification and role in virulence of putative iron acquisition genes from Corynebacterium pseudotuberculosis. FEMS Microbiol Lett. 2002, 208: 41-45. 10.1111/j.1574-6968.2002.tb11058.x.View ArticlePubMedGoogle Scholar
- Chaplin PJ, de Rose R, Boyle JS, McWaters P, Kelly J, Tennent JM, Lew AM, Scheerlinck JP: Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect Immun. 1999, 67: 6434-6438.PubMed CentralPubMedGoogle Scholar
- De Rose R, Tennent J, McWaters P, Chaplin PJ, Wood PR, Kimpton W, Cahill R, Scheerlinck JP: Efficacy of DNA vaccination by different routes of immunisation in sheep. Vet Immunol Immunopathol. 2002, 90: 55-63. 10.1016/S0165-2427(02)00221-0.View ArticlePubMedGoogle Scholar
- Haynes JA, Tkalcevic J, Nisbet IT: Production of an enzymatically inactive analog of phospholipase D from Corynebacterium pseudotuberculosis. Gene. 1992, 119: 119-121. 10.1016/0378-1119(92)90075-Z.View ArticlePubMedGoogle Scholar
- Hodgson AL, Krywult J, Corner LA, Rothel JS, Radford AJ: Rational attenuation of Corynebacterium pseudotuberculosis: potential cheesy gland vaccine and live delivery vehicle. Infect Immun. 1992, 60: 2900-2905.PubMed CentralPubMedGoogle Scholar
- Hodgson AL, Carter K, Tachedjian M, Krywult J, Corner LA, McColl M, Cameron A: Efficacy of an ovine caseous lymphadenitis vaccine formulated using a genetically inactive form of the Corynebacterium pseudotuberculosis phospholipase D. Vaccine. 1999, 17: 802-808. 10.1016/S0264-410X(98)00264-3.View ArticlePubMedGoogle Scholar
- McNamara PJ, Bradley GA, Songer JG: Targeted mutagenesis of the phospholipase D gene results in decreased virulence of Corynebacterium pseudotuberculosis. Mol Microbiol. 1994, 12: 921-930. 10.1111/j.1365-2958.1994.tb01080.x.View ArticlePubMedGoogle Scholar
- Moore RJ, Rothel L, Krywult J, Radford AJ, Lund K, Hodgson AL: Foreign gene expression in Corynebacterium pseudotuberculosis: development of a live vaccine vector. Vaccine. 1999, 18: 487-497. 10.1016/S0264-410X(99)00243-1.View ArticlePubMedGoogle Scholar
- Moore RJ, Stewart DJ, Lund K, Hodgson AL: Vaccination against ovine footrot using a live bacterial vector to deliver basic protease antigen. FEMS Microbiol Lett. 2001, 194: 193-196. 10.1111/j.1574-6968.2001.tb09468.x.View ArticlePubMedGoogle Scholar
- Pogson CA, Simmons CP, Strugnell RA, Hodgson ALM: Cloning and manipulation of the Corynebacterium pseudotuberculosis recA gene for live vaccine vector development. FEMS Microbiol Lett. 1996, 142: 139-145. 10.1111/j.1574-6968.1996.tb08421.x.View ArticlePubMedGoogle Scholar
- Simmons CP, Hodgson AL, Strugnell RA: Attenuation and vaccine potential of aroQ mutants of Corynebacterium pseudotuberculosis. Infect Immun. 1997, 65: 3048-3056.PubMed CentralPubMedGoogle Scholar
- Simmons CP, Dunstan SJ, Tachedjian M, Krywult J, Hodgson AL, Strugnell RA: Vaccine potential of attenuated mutants of Corynebacterium pseudotuberculosis. Infect Immun. 1998, 66: 474-479.PubMed CentralPubMedGoogle Scholar
- Tachedjian M, Krywult J, Moore RJ, Hodgson AL: Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Vaccine. 1995, 13: 1785-1792. 10.1016/0264-410X(95)00144-P.View ArticlePubMedGoogle Scholar
- Stanford K, Brogden KA, McClelland LA, Kozub GC, Audibert F: The incidence of caseous lymphadenitis in Alberta sheep and assessment of impact by vaccination with commercial and experimental vaccines. Can J Vet Res. 1998, 62: 38-43.PubMed CentralPubMedGoogle Scholar
- Alves FSF, Santiago LB, Pinheiro RR: Linfadenite caseosa: o estado da arte. 2007, Sobral: Embrapa Caprinos, [http://www.cnpc.embrapa.br/admin/pdf/033204001201512.doc74.pdf]Google Scholar
- Gibson CM, Caparon MG: Alkaline phosphatase reporter transposon for identification of genes encoding secreted proteins in gram-positive microorganisms. Appl Environ Microbiol. 2002, 68: 928-932. 10.1128/AEM.68.02.928-932.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Rebouças MF, Portela RW, Lima DD, Loureiro D, Bastos BL, Moura-Costa LF, Vale VL, Miyoshi A, Azevedo V, Meyer R: Corynebacterium pseudotuberculosis secreted antigen-induced specific gamma-interferon production by peripheral blood leukocytes: potential diagnostic marker for caseous lymphadenitis in sheep and goats. J Vet Diagn Invest. 2011, 23: 213-220. 10.1177/104063871102300204.View ArticlePubMedGoogle Scholar
- GraphPad Software, Inc. [http://www.graphpad.com]
- Lan DT, Makino S, Shirahata T, Yamada M, Nakane A: Tumor necrosis factor alpha and gamma interferon are required for the development of protective immunity to secondary Corynebacterium pseudotuberculosis infection in mice. J Vet Med Sci. 1999, 61: 1203-1208. 10.1292/jvms.61.1203.View ArticlePubMedGoogle Scholar
- Paule BJ, Azevedo V, Regis LF, Carminati R, Bahia CR, Vale VL, Moura-Costa LF, Freire SM, Nascimento I, Schaer R, Goes AM, Meyer R: Experimental Corynebacterium pseudotuberculosis primary infection in goats: kinetics of IgG and interferon-gamma production, IgG avidity and antigen recognition by Western blotting. Vet Immunol Immunopathol. 2003, 96: 129-139. 10.1016/S0165-2427(03)00146-6.View ArticlePubMedGoogle Scholar
- Shaw T, Thomas LH, Friedland JL: Regulation of IL-10 secretion after phagocytosis of Mycobacterium tuberculosis by human monocytic cells. Cytokine. 2000, 12: 483-486. 10.1006/cyto.1999.0586.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.